Artículos por temáticas

Ultrasound guided alcohol neurolysis of musculocutaneous nerve to relieve elbow spasticity in hemiparetic stroke patients.

Lee DG, Jang SH.

NeuroRehabilitation. 2012;31(4):373-7. doi: 10.3233/NRE-2012-00806.

Assessing the neurophysiological effects of botulinum toxin treatment for adults with focal limb spasticity: a systematic review.

Phadke CP, Ismail F, Boulias C.

Disabil Rehabil. 2012;34(2):91-100. doi: 10.3109/09638288.2011.591882. Review.

Development of the Persian version of the Modified Modified Ashworth Scale: translation, adaptation, and examination of interrater and intrarater reliability in patients with poststroke elbow flexor spasticity.

Nakhostin Ansari N, Naghdi S, Forogh B, Hasson S, Atashband M, Lashgari E.

Disabil Rehabil. 2012;34(21):1843-7. doi: 10.3109/09638288.2012.665133.

Spasticity following spinal cord injury.

Rekand T, Hagen EM, Grønning M.

Tidsskr Nor Laegeforen. 2012 Apr 30;132(8):970-3. doi: 10.4045/tidsskr.10.0872. Review. English, Norwegian.

[Pathophysiology of spasticity].

Marque P, Brassat D.

Rev Neurol (Paris). 2012 Apr;168 Suppl 3:S36-44. doi: 10.1016/S0035-3787(12)70045-0. Review. French.

Effectiveness of switching therapy from complexing protein-containing botulinum toxin type A to a formulation with low immunogenicity in spasticity after stroke: a case report.

Santamato A, Ranieri M, Panza F, Frisardi V, Micello MF, Filoni S, Fiore P.

J Rehabil Med. 2012 Sep;44(9):795-7. doi: 10.2340/16501977-1009.

[Non-medicinal treatments of spasticity in multiple sclerosis].

Mailhan L, Papeix C.

Rev Neurol (Paris). 2012 Apr;168 Suppl 3:S57-61. doi: 10.1016/S0035-3787(12)70048-6. Review. French.

The use of botulinum toxin type A in the management of adult-onset focal spasticity: a survey of Australian allied health professionals.

Williams G, Olver J, de Graaff S, Singer BJ.

Aust Occup Ther J. 2012 Aug;59(4):257-64. doi: 10.1111/j.1440-1630.2012.01027.x.

Spasticity.

Dietz V, Sinkjaer T.

Handb Clin Neurol. 2012;109:197-211. doi: 10.1016/B978-0-444-52137-8.00012-7. Review.

Cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A: results from the botulinum toxin for the upper limb after stroke (BoTULS) trial.

Shackley P, Shaw L, Price C, van Wijck F, Barnes M, Graham L, Ford GA, Steen N, Rodgers H.

Toxins (Basel). 2012 Dec;4(12):1415-26.

Immediate effects of electrical stimulation combined with passive locomotion-like movement on gait velocity and spasticity in persons with hemiparetic stroke: a randomized controlled study.

Yamaguchi T, Tanabe S, Muraoka Y, Masakado Y, Kimura A, Tsuji T, Liu M.

Clin Rehabil. 2012 Jul;26(7):619-28. doi: 10.1177/0269215511426803.

Perceived impact of spasticity is associated with spatial and temporal parameters of gait in multiple sclerosis.

Balantrapu S, Sandroff BM, Sosnoff JJ, Motl RW.

ISRN Neurol. 2012;2012:675431. doi: 10.5402/2012/675431.

Estimation of botulinum toxin type A efficacy on spasticity and functional outcome in children with spastic cerebral palsy.

Colovic H, Dimitrijevic L, Stankovic I, Nikolic D, Radovic-Janosevic D.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012 Mar;156(1):41-7. doi: 10.5507/bp.2012.017.

Patient registry of outcomes in spasticity care.

Esquenazi A, Mayer N, Lee S, Brashear A, Elovic E, Francisco GE, Yablon S; PROS Study Group..

Am J Phys Med Rehabil. 2012 Sep;91(9):729-46. doi: 10.1097/PHM.0b013e31824fa9ca.

Management of spasticity in progressive multiple sclerosis: efficacy of repeated intrathecal triamcinolone acetonide administration.

Abu-Mugheisib M, Benecke R, Zettl UK.

Curr Pharm Des. 2012;18(29):4564-9. Review.